The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Acta Diabetologica

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00592-014-0604-0PMID 25430705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.

  2014cited by this paper
• Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials

  2013cited by this paper
• Efficacy and safety of degludec insulin: a meta-analysis of randomised trials

  2013cited by this paper
• Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers.

  2013cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Current clinical status, glucose control, and complication rates of children and youth with type 1 diabetes in Rwanda

  2013cited by this paper
• Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

  2013cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

  2012cited by this paper
• Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

  2012cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• The impact of non-severe hypoglycemic events on work productivity and diabetes management.

  2011cited by this paper
• Insulin Degludec in Type 1 Diabetes

  2011cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions

  2010cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Is glycaemia or insulin dose the stronger risk factor for coronary artery disease in type 1 diabetes?

  2009cited by this paper
• Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes

  2007cited by this paper
• Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes

  2006cited by this paper
• Hypoglycemia in children with type 1 diabetes: current issues and controversies

  2003cited by this paper
• Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort)

  2003cited by this paper
• The pathophysiology of hypoglycaemia in diabetes.

  2002cited by this paper
• Diabetes Control and Complications Trial

  1993cited by this paper

• Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers

  2025cites this paper
• Degludec insulin versus efsitora insulin in diabetes mellitus management: A systematic review and meta-analysis.

  2025cites this paper
• Análogos de la insulina. ¿Cuál es su lugar en la terapéutica?

  2022cites this paper
• The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future

  2021cites this paper
• Ultralong Analogue Insulin Degludec in Type 1 Diabetes : Reduction of Hypoglycemic Events

  2021cites this paper
• Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial

  2021cites this paper
• Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.

  2021cites this paper
• Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future

  2021cites this paper
• Diabetes mellitus type 1 in adults

  2020cites this paper
• DEGLUDEC INSULIN IN TYPE 1 DIABETIC PATIENTS: 18 MONTHS OF OBSERVATION

  2020influential citation
• Monitoring and management of hyperglycemia in patients with advanced diabetic kidney disease.

  2020cites this paper
• Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review

  2020cites this paper
• Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials

  2019cites this paper
• Patient Assessment in Clinical Pharmacy

  2019cites this paper
• Predicting different factors that affect hospital utilization and outcomes Among diabetic patients admitted with hypoglycemia using structural equation modeling.

  2019cites this paper
• Glycemic Management in Adults With Type 1 Diabetes.

  2018cites this paper
• Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.

  2018cites this paper
• Factors Influencing Variations in Hospitalization for Diabetes with Hypoglycemia

  2018cites this paper
• Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial

  2018cites this paper
• Adjustment of insulin doses when switching from glargine 100 U/ml or detemir to degludec: an observational study

  2018cites this paper
• Advances in Care for Insulin-Requiring Patients Without Closed Loop

  2018cites this paper
• Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials

  2018cites this paper
• Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry.

  2017cites this paper
• Factors Influencing Hypoglycemia Care Utilization and Outcomes Among Adult Diabetic Patients Admitted to Hospitals: A Predictive Model

  2017cites this paper
• Continuous subcutaneous insulin infusion—an opportunity for better care but not a “magic pill”

  2017cites this paper
• Short-Acting Insulin Reduction Strategies for Continuous Cycle Ergometer Exercises in Patients with Type 1 Diabetes Mellitus

  2017cites this paper
• Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus

  2017cites this paper
• Prediction of nocturnal hypoglycemia unawareness by fasting glucose levels or post-breakfast glucose fluctuations in patients with type 1 diabetes receiving insulin degludec: A pilot study

  2017cites this paper
• Management of Adults With Diabetes and Cognitive Problems

  2016cites this paper
• Reg3g overexpression promotes β cell regeneration and induces immune tolerance in nonobese‐diabetic mouse model

  2016cites this paper
• Controlled release of biologics for the treatment of type 2 diabetes.

  2016cites this paper
• New drugs 2015, part 1.

  2015cites this paper
• Long-acting insulin analogs in type 1 diabetes : effects on metabolic control, endogenous insulin production and the GH-IGF-axis

  2015cites this paper